Diagnos Settles Debt with Shares
Analysis based on 8 articles · First reported Jun 18, 2026 · Last updated Jun 18, 2026
The market impact on Diagnosis is likely mixed; while the company preserves cash by issuing shares, this action will dilute existing shareholder value. The settlement is subject to regulatory approval from the TSX Venture Exchange, which could influence investor confidence.
Diagnosis, a publicly traded Canadian corporation focused on AI for eye-related health, announced its intention to settle two demand loans totaling C$125,000. The settlement will involve issuing 625,000 common shares at C$0.20 per share to the lenders, with accrued interest paid in cash. This move is intended to preserve Diagnosis's cash reserves. The agreements were dated June 18, 2026, with an anticipated settlement date of June 25, 2026. The transaction is contingent on regulatory acceptance from the TSX Venture Exchange.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard